DucommunDCO
DCO logo
Fair Value
US$164
Share price25 Jun
US$189.1815.4% overvalued intrinsic discount
Loading
1Y122.80%
7D2.58%

Defense Modernization And Aerospace Recovery Will Reshape Markets

Analyst Consensus Target compiles analysts opinions to create narratives on stocks using the Analysts Consensus Price Target, forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published
16 Sep 24
Updated
25 Jun 26
Views
162
Not Invested

Last Update 25 Jun 26

DCO: Q1 Execution And Aero Recovery Will Balance Restatement Governance Risks

Analysts have lifted their blended price target on Ducommun to approximately $164, reflecting updated models following the company’s Q1 earnings beat and improving commercial aerospace trends, alongside ongoing destocking concerns.

Analyst Commentary on Ducommun

Recent research on Ducommun points to a generally constructive tone, with price targets raised across multiple firms following the Q1 report and sector model updates, while still flagging a few key risks around end market trends and inventory normalization.

Bullish Takeaways

  • Bullish analysts highlight Ducommun's Q1 performance, pointing to adjusted EBITDA of $35.4M that came in above prior consensus estimates. They view this as evidence of solid execution and cost control.
  • Several reports tie the higher price targets to stronger than anticipated commercial aerospace activity. Production deliveries and higher OEM production rates supported revenue and margin outcomes in the quarter.
  • Model updates across aerospace and defense coverage have led bullish analysts to raise their valuation ranges for Ducommun. These updates reflect revised assumptions around earnings power following the Q1 beat.
  • Some analysts also reference sector-wide selloffs as creating what they see as more attractive entry levels for Ducommun, particularly if aerospace exposure is prioritized over defense in any future rebounds.

Bearish Takeaways

  • Even with raised targets, cautious analysts emphasize that destocking in commercial aerospace supply chains is still expected to be an issue over the coming quarters. This could weigh on Ducommun's near term volume and visibility.
  • Inventory adjustments at customers, including large OEM programs, are flagged as a potential headwind that could limit how quickly recent strength in production flows through to Ducommun's results.
  • Sector commentary points to geopolitical uncertainty, particularly around the Middle East conflict, as a factor that could cap the speed of any broad rebound in aerospace and defense stocks. This would also affect sentiment toward Ducommun.
  • Past target reductions referenced in earlier research illustrate that analysts remain sensitive to shifts in order trends or earnings expectations. This underscores that Ducommun's valuation could move quickly if execution or sector assumptions change.

What’s in the News for Ducommun

  • Ducommun announced plans to restate its financial statements for 2024 and 2025 related to the timing of stock based compensation expense recognition, and stated that the previously issued statements for those years are unreliable, according to The Schall Law Firm.
  • The Schall Law Firm launched an investigation on behalf of Ducommun investors into potential securities law violations tied to the financial restatements and related disclosures, with the announcement noting that the restatement coincided with a decline in the stock price.
  • Rep. Gil Cisneros, a member of the U.S. House Armed Services Committee, disclosed multiple purchases of Ducommun stock since September, drawing attention because the company supplies missiles and weapons components for U.S. Special Operations, according to recent media reports.
  • Ducommun scheduled an Analyst and Investor Day focused on progress under its VISION 2027 plan and the introduction of a new five year road map called VISION 2032.
  • Company executives stated on the Ducommun first quarter 2026 earnings call that the company is actively pursuing acquisitions, highlighting a new US$650 million credit facility that they indicated lowers its cost of capital and increases capacity to fund potential deals.

Valuation Changes for Ducommun

  • Fair Value: Blended fair value remains at $164.0, indicating no change in the central valuation output from prior assumptions.
  • Discount Rate: The discount rate edges down slightly from 8.24% to 8.22%, a modest adjustment in the required return used to value Ducommun.
  • Revenue Growth: The long term revenue growth assumption is essentially unchanged at about 8.12%, with only a minor numerical refinement.
  • Net Profit Margin: The net profit margin assumption holds steady at roughly 12.63%, reflecting no material shift in modeled profitability for Ducommun.
  • Future P/E: The future P/E multiple is adjusted marginally from 23.23x to 23.22x, a very small change in the valuation multiple applied to earnings.
1 viewusers have viewed this narrative update

Key Takeaways

  • Expansion in defense and commercial aerospace, driven by rising demand and modernization, positions Ducommun for sustained top-line growth and increased order activity.
  • Strategic focus on higher-margin products, automation, and domestic sourcing is improving margins, cash flow stability, and overall earnings quality.
  • Heavy dependence on volatile aerospace and defense markets, operational execution challenges, and uncertainty in acquisitions threaten Ducommun's revenue growth, margin stability, and diversification efforts.

Catalysts

About Ducommun
    Provides engineering and manufacturing services for products and applications used in the aerospace and defense, industrial, medical, and other industries in the United States.
What are the underlying business or industry changes driving this perspective?
  • Elevated global defense spending and the replenishment of missile and radar inventories-highlighted by strong double-digit growth in both segments and a 30% increase in missile backlog-positions Ducommun to sustain and expand revenue as defense modernization accelerates over the next several years, with increasing program content and order activity.
  • Strengthening demand for commercial aircraft, particularly with increasing Boeing 737 and 787 build rates and projected end to destocking in 2025/2026, underpins a likely recovery and longer-term rebound in top-line growth for Ducommun's commercial aerospace business.
  • Ongoing mix shift toward higher-margin engineered products and aftermarket (maintained at 23% of revenues, moving toward 25%+), together with value-driven pricing and restructuring actions, is increasing gross margins (recorded at 26.6% in Q2), which supports sustained improvements in net margins and earnings.
  • Facility consolidations, automation, and digital initiatives expected to generate $11-13 million in annual savings (with full benefits ramping in late 2025–2026), set the stage for further operating margin expansion and better cash flow conversion (targeting 100% in the coming years).
  • Minimal exposure to tariff impacts, and high percentage of domestic production and sourcing, should allow Ducommun to capitalize on the industry-wide shift toward supply chain localization, potentially capturing increased market share and stabilizing contract flows, thereby reducing earnings volatility and supporting stable free cash flow.
Ducommun Earnings and Revenue Growth

Ducommun Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

  • Analysts are assuming Ducommun's revenue will grow by 8.1% annually over the next 3 years.
  • Analysts assume that profit margins will increase from -3.4% today to 12.6% in 3 years time.
  • Analysts expect earnings to reach $134.3 million (and earnings per share of $5.52) by about June 2029, up from -$28.8 million today.
  • In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 24.1x on those 2029 earnings, up from -86.5x today. This future PE is lower than the current PE for the US Aerospace & Defense industry at 38.9x.
  • Analysts expect the number of shares outstanding to grow by 1.08% per year for the next 3 years.
  • To value all of this in today's terms, we will use a discount rate of 8.22%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?
  • Ducommun continues to face significant cyclical risk connected to commercial aerospace customers like Boeing and Spirit AeroSystems; persistent destocking and uncertain ramp-up timelines introduce volatility in aerospace revenue, which could negatively impact top-line growth in low-demand cycles.
  • There is a growing concentration of revenue from the defense sector, especially missile and radar programs, exposing the company to shifts in U.S. government defense budgets and platform priorities-potentially impacting both revenue and margin stability if defense spending slows or focus shifts away from Ducommun's key franchises.
  • Execution risks associated with facility consolidation, product line recertification, and transitioning work to new or lower-cost locations (such as the ramp-up at Coxsackie and Guaymas) may lead to unforeseen production delays, temporary operating inefficiencies, or customer disruptions, adversely affecting near
  • and mid-term margins and earnings.
  • Ducommun's ability to scale up its higher-margin engineered product and aftermarket portfolio partly hinges on successful and timely acquisitions; intensifying competition for quality assets or delayed/integrated acquisitions could slow margin expansion and inhibit revenue diversification, limiting the pace of long-term earnings growth.
  • Sustained pressure from unfavorable sales mix (as seen in lower Structural Systems margins) and ongoing restructuring costs, combined with reliance on favorable product mix for margin gains, may challenge the company's ability to consistently expand net margins and achieve targeted profitability if market or execution tailwinds weaken.

Valuation

How have all the factors above been brought together to estimate a fair value?

  • The analysts have a consensus price target of $164.0 for Ducommun based on their expectations of its future earnings growth, profit margins and other risk factors.
  • However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $187.0, and the most bearish reporting a price target of just $150.0.
  • In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $1.1 billion, earnings will come to $134.3 million, and it would be trading on a PE ratio of 24.1x, assuming you use a discount rate of 8.2%.
  • Given the current share price of $165.31, the analyst price target of $164.0 is 0.8% lower. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
  • We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Ducommun?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Read more narratives

Fair Value vs Share Price

US$164
vs US$189.1815.4% overvalued intrinsic discount
PastFuture-57m1b2015201820212024202620272029Revenue US$1.1bEarnings US$134.3m
8.1%
Revenue growth
12.6%
Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Ducommun

  • Fair value estimate changes
  • Narrative and analyst updates
  • Key company announcements

Company analysis

Excellent balance sheet with moderate growth potential.

Market capUS$2.8b
PB4.3x
Estimated Growth8.0%
Dividend YieldN/A
Full analysis

CEO & management

Stephen Oswald
CEO
8.8yrs
CEO Tenure

Provides engineering and manufacturing services for products and applications used in the aerospace and defense, industrial, medical, and other industries in the United States.